Delivery Order SPE2DB20D1109-SPE2DB22FQ08U

Award Date 9/15/22
Potential Completion Date 9/16/22
Potential Value $1.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,338,659 units of Doxycycline Hyclate 100 mg tablets, a generic antibiotic medication, with a ceiling value of $2,551.68. The contract is a Firm Fixed Price Delivery Order, with a period of performance through February 24, 2025. This contract is not designated as a set-aside...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,560,074,952 units of Doxycycline Hyclate 100mg tablets. The $2,209.34 firm fixed-price contract has a period of performance through February 28, 2023. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., valued at up to $999,999,999.00 and running through November...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4,567,482,551 units of Doxycycline Hyclate 100 mg tablets, a common antibiotic medication. The contract has a ceiling value of $2,126.40 and an ultimate completion date of March 7, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,630.73 firm fixed-price delivery order is for the provision of 4,559,305,900 units of Doxycycline Hyclate 100 mg tablets, with a completion date of December 8, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,406,332 units of doxycycline hyclate 100 mg tablets, with a ceiling value of $1,501.92. It is a firm fixed-price delivery order contract with a performance period through February 28, 2025. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract has an award value of $1,324.65 and is a delivery order with a firm fixed price pricing type. The contract is for the supply of 4,567,254,166 units of Doxycycline Hyclate 100 mg tablets, a pharmaceutical product used in medical treatment. The contract has an ultimate completion date of February 13, 2025. This...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,566,419,546 units of Doxycycline Hyclate 50 mg delayed-release tablets, with a ceiling value of $4,592.97. The contract is a firm-fixed-price delivery order with a period of performance through November 14, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract...
This federal contract award, with ID SPE2DB22D3501|SPE2DB23FTR82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,559,255,906 units of doxycycline hyclate 100 mg tablets. The $1,644.16 firm-fixed-price delivery order has an ultimate completion date of December 5, 2022. This award is not associated with a set-aside program. AmerisourceBergen, through its Corporate Office division, holds significant...
This federal contract award is a delivery order issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The order, valued at $1,156.07, is for the delivery of 4,560,447,359 units of Doxycycline Hyclate 100 mg tablets. The contract has a firm fixed price and has an ultimate completion date of April 3, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Doxycycline Hyclate 100 mg tablets, with a ceiling value of $2,138.67 and a performance period ending in October 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
  • SPE2DB20D1109
    Indefinite Delivery Contract
  • SPE2DB20D1109-SPE2DB22FQ08U
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,275.79 firm fixed-price contract is for the delivery of 4,558,471,599 Doxycycline Hyclate 100 mg tablets. The contract has a period of performance ending on September 16, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. This contract award does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 10:54 AM